Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Leuk Res. 2021 Oct 21;111:106733. doi: 10.1016/j.leukres.2021.106733

Figure 3. Bone marrow (BM) blasts counts and MYC protein expression levels.

Figure 3.

BM blasts counts at the time of MDS (A) and AML-MRC (B) diagnosis are not statistically different between low vs. high MYC groups. MYC protein expression level at the time of AML progression is significantly higher compared to the level at MDS diagnosis (C). In individual patients, a total of 18 and 3 patients had at least 5% increase and decrease, respectively, in MYC expression level at the time of AML progression when compared with the baseline MYC at MDS diagnosis (D). A total of 20 patients had less than 5% changes in MYC expression levels at the time of AML progression compared to MDS diagnosis.